My watch list  

102 Current news of Pfizer


You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
Anokion Announces $35 Million Equity Investment from Pfizer

Funding Supports Advancement of KAN-101 for Celiac Disease into Phase 2 Clinical Development


Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced that Pfizer has made a $35 million equity investment in Anokion through the Pfizer Breakthrough Growth Initiative. In conjunction with the investment, Michael ...


image description
Pfizer will invest €90.5 million in Valneva

Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15


Valneva SE and Pfizer Inc. announced that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15. As previously announced on April 26, 2022, Pfizer plans to initiate the Phase 3 study ...


image description
Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program

The mRNA technology could to improve upon the efficacy of current flu vaccines


Pfizer Inc. announced that the first participants have been dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and immunogenicity of a single dose quadrivalent mRNA vaccine against influenza in healthy adults. Pfizer’s mRNA influenza vaccine program is the first in a planned ...


image description
FDA Approves First COVID-19 Vaccine


The U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also ...


image description
Iktos Announces Collaboration With Pfizer in AI for Drug Design

“We are proud to work with Pfizer and to have their scientists use our software in their early discovery programs”


Iktos announced the application of Iktos Artificial Intelligence technology for de novo design to selected Pfizer small-molecule discovery programs. Over the last few years, phenomenal advances in AI algorithmic development and computational power have enabled innovative approaches in ...


image description
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study

Candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis


Pfizer Inc. and BioNTech SE announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 ...


image description
BioNTech and Pfizer test COVID-19 Vaccine Candidate in Germany

Regulatory Approval From Paul-Ehrlich-Institut to Commence German Part of Global Phase 2/3 Trial Received


BioNTech SE and Pfizer Inc. announced that the German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 2/3 clinical trial in Germany for their BNT162b2 vaccine candidate. The study in Germany is part of the global pivotal Phase 2/3 program BioNTech and Pfizer initiated in ...


image description
Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate

Doses expected to be delivered in 2020 and 2021


Pfizer Inc. and BioNTech SE announced an agreement with the United Kingdom to supply 30million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, currently in development, subject to clinical success and regulatory approval. Financial details of the agreement were not ...


image description
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2

Efforts to manufacture the leading candidates, at risk, are gearing up


Pfizer Inc. and BioNTech SE announced preliminary U.S. data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2, the virus causing the current global pandemic. The BNT162 program is evaluating at ...


image description
Pfizer and BioNTech to Accelerate Global COVID-19 Vaccine Development


BioNTech SE and Pfizer Inc. disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine program, previously announced on March 17, 2020. The collaboration aims to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on ...


Page 1 From 11
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE